Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus chemotherapy for perioperative esophageal squamous carcinoma
NCT07019181Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Pathological Complete Response Rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07019181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07019181.